There is a fungus living in the soil and trees of the Pacific Northwest that can cause serious pneumonia and meningitis in people who were perfectly healthy before they inhaled it. All true. In any given year it is also close to a non-event, because Washington reported three cases in 2024 and zero in both 2022 and 2023 (1).
Both facts belong together. They almost never land that way. That is how a region collects years of alarming headlines about an organism most physicians here will never diagnose.
What it actually is
Cryptococcus gattii is an environmental yeast. Isolated from native trees, soil, air, and water across the Pacific Northwest (2). You breathe it in. That is the only route. It does not pass between people, and you cannot catch it from an infected dog or cat (2)(3). It surfaced in 1999, in people and animals on Vancouver Island. Oregon’s first human case came in December 2004 (4). Washington’s came in 2006 (2).
Then there is the incubation period, the strangest feature of this organism: the average interval between inhaling the spores and falling ill runs six to seven months, the documented range stretches from two months out to 13, and it can be years, which is why investigators frequently cannot say where a person picked it up (2)(4). Not weeks. Months.
The numbers, in full
Washington publishes its counts by year. From 2016 through 2024, in order: five cases, one, four, two, three, three, zero, zero, three (1). Twenty one cases in nine years statewide. Two deaths across that whole span, and an annual rate that never rose above 0.1 per 100,000 (1). From the first Washington case in 2006 through December 2019, the state total was 58 cases and nine deaths (2).
Oregon makes the same point from another angle. In 2022, Oregon residents accounted for 69 reported cryptococcal infections of all species combined. Two were C. gattii (4).
Even at the epicenter, at the peak, the risk stayed small. Vancouver Island, the hardest hit place on the continent, ran roughly 25 cases per million residents per year from 1999 through 2007 (5). Per million. Per year.
The claim that it attacks healthy people deserves tightening
This is the line that powered the old news coverage. It also needs a second look. C. gattii does differ from C. neoformans, which typically infects people who are already immunocompromised (2). C. gattii can infect people with intact immune systems. It does.
Then look at who actually got sick. Among Oregon and Washington patients from 2004 to 2011, 51 percent had a documented immunocompromising condition. Median age 54 (6). Washington’s guidance names the groups more likely to develop disease: immunocompromise, existing lung conditions, age over 50, tobacco use (2). Oregon puts it flatly: healthy persons appear to be at low risk, and most infections occur among immunocompromised or chronically ill people (4). So my read is that immunocompetence fails to protect you the way it does against C. neoformans, while age, lungs and immune status still move you up or down the list, and that second half almost never got printed. Both halves matter.
When it does happen, it is serious. Very. Published mortality runs 13 to 33 percent (2)(7), and in the Pacific Northwest cohort 13 of 70 patients, 19 percent, died within three months of diagnosis (6). Untreated cryptococcal meningitis kills within weeks to months (2). The rarity is what makes this a poor thing to worry about, and the severity is what makes it a good thing to remember.
If you live here and this worries you
I will be direct. There is no screening test worth doing and no vaccine. No avoidance strategy works either, and Washington’s guidance states that outright (2)(4). You cannot stay away from trees and soil here. You should not try.
Duration is what you can pay attention to. The presentation that matters is a cough measured in weeks to months rather than days, often with shortness of breath, fever, night sweats, or loss of appetite (2). Outlasted one course of antibiotics, then a second? Push for a chest image instead of a third prescription. The other pattern is neurological. Headache that will not quit, neck pain, light sensitivity, or a change in thinking that people around you notice before you do (2).
None of that is specific to C. gattii. A two month cough in Seattle is far more likely to be asthma, reflux, or post-viral airway irritation. Which is my point. The right response to a long cough is identical whether or not this organism exists. So you need not carry it around.
This stays a clinician-facing subject. Patients do not, for the most part, bring the organism to me by name, and given the numbers above there is no reason they should.
When a clinician should genuinely think of it
Two situations, both narrow.
The first is a pulmonary infiltrate or nodule that will not respond to antibacterials in someone with Pacific Northwest exposure. Cryptococcomas, mass lesions in lung or brain, sometimes surface on imaging ordered for something else (2)(4). The second is unexplained central nervous system disease. A subacute meningitis in someone who does not fit the usual profile. In the Oregon and Washington series, 47 percent of infections were pulmonary and 43 percent involved the CNS (6).
Ask about the past two years of travel and outdoor activity. Not the past two weeks (2). With an incubation that can exceed a year, a recent exposure history tells you nothing.
The diagnostic trap is worth spelling out. Cryptococcal antigen testing on serum or CSF is fast and useful for establishing that cryptococcal disease is present. It will not give you the species (2)(3). Identifying C. gattii requires an isolate, speciated on canavanine-glycine-bromothymol blue agar or by MALDI-TOF, with genotyping at CDC (2)(3), which is why Oregon’s public health division says outright that the shift from culture toward antigen testing has made it impossible to advance knowledge of C. gattii epidemiology (4). So submit the isolate. Reporting is required either way. Three business days in Washington, one working day in Oregon (2)(3).
Treatment follows standard cryptococcal principles. Fluconazole for asymptomatic through moderate pulmonary infection, amphotericin B with flucytosine for severe pulmonary or CNS disease, continued at least six months (2).
Routing matters here, because a video visit produces neither of the two things this diagnosis needs. No image. No isolate. Suspected pneumonia, fungal or otherwise, goes one of three ways from me: primary care first in principle and least often in practice, because getting an appointment there is hard, then urgent care, which is where most of it actually lands. Where there is no urgent care within reach, that leaves the emergency department.
The Bottom Line
Cryptococcus gattii is real. It lives here, and it can hurt someone with a normal immune system. It is also rare enough that Washington logged zero cases in two consecutive recent years (1). If you have a cough in the Northwest, this is almost certainly not it, and the reason to get a persistent cough evaluated has nothing to do with fungus; if you are a clinician holding a lung lesion or a meningitis that antibacterials are not touching, put it on the differential and hang onto the isolate.
The 2010 coverage framed this as a menace creeping toward your city. Two decades of surveillance data say something quieter. Small numbers. Serious illness when it happens. A narrow set of reasons to suspect it at all.
Sources
1. Washington State Department of Health. Communicable Disease Annual Report 2024 (published December 2025), Cryptococcosis (by Cryptococcus gattii) narrative and data table. https://doh.wa.gov/sites/default/files/2025-12/420-004-CDAnnualReport2024.pdf
2. Washington State Department of Health. Cryptococcus gattii Reporting and Surveillance Guidelines, DOH 420-050 (updates through June 2024). https://doh.wa.gov/sites/default/files/2025-08/420-050-Guideline-Cgattii.pdf
3. Oregon Health Authority, Public Health Division, Acute and Communicable Disease Prevention. Cryptococcosis Investigative Guidelines 2026 (updated May 2026). https://www.oregon.gov/oha/PH/DISEASESCONDITIONS/COMMUNICABLEDISEASE/REPORTINGCOMMUNICABLEDISEASE/REPORTINGGUIDELINES/Documents/cryptococcus.pdf
4. Oregon Health Authority. Oregon’s 2022 Selected Reportable Communicable Disease Summary, Cryptococcosis section. https://www.oregon.gov/oha/PH/DISEASESCONDITIONS/COMMUNICABLEDISEASE/DISEASESURVEILLANCEDATA/ANNUALREPORTS/Documents/2022-Annual-Communicable-Disease-Report.pdf
5. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007. Emerging Infectious Diseases 2010;16(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC2958008/
6. Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest. PLOS ONE 2014;9(2):e88875. https://pmc.ncbi.nlm.nih.gov/articles/PMC3929541/
7. CDC (archived page, last reviewed May 26, 2020). C. gattii Infection Statistics. Current cdc.gov fungal disease pages were unreachable at the time of writing, so the CDC archive is cited. https://archive.cdc.gov/www_cdc_gov/fungal/diseases/cryptococcosis-gattii/statistics.html
Related Reading
What Is Hantavirus? What You Need to Know Right Now
Tuberculosis in 2025: Kansas Outbreak, Vaccines, and Staying Safe
What Causes a Cough and What Are the Treatment Options?
Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine
This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.